Seeking Alpha
14 Sept 2026, 05:15 UTC · 2h ago
Verdict
Headline leans bearish. We score EXEL −0.20 across four claims.
Score confirms the headline.
EXEL score
−0.20
More negative than 68% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA has extended the review period for Exelixis' zanzalintinib by three months.
More negative than 72% of claims this week
No new clinical failures or safety signals were disclosed regarding the FDA extension.
More positive than 55% of claims this week
Continue reading
5 related stories
Top 1 mover · tap to explore
Exelixis' 2026 guidance does not include launch revenue for zanzalintinib.
More positive than 47% of claims this week
CABOMETYX continues to experience growth.
So whatSteady performance of a core product provides a fundamental valuation floor despite pipeline delays.
More positive than 47% of claims this week
Which stocks this story touches
More negative than 68% of ticker scores this week
The FDA extended the review period for zanzalintinib, delaying a potential new revenue stream.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
10h ago
Price reaction
Expected −0.20Actual —
EXEL hasn't traded since this ran. Last close $56.12 (Sep 11); the reaction starts at the next open.
EXEL chart →
